lichen planopilaris. Lichen planopilaris
Conditions
Interventions
Intervention 1: Intervention group: this group receives Rhofanib (Tofacitinib) 5mg twice a day with concurrent topical clobetasol for 6 months and then will be followed for 3 months after cessation of
Sponsors
Nanoalvand Co.
Eligibility
Sex/Gender
All
Age
18 Years to 55 Years
Inclusion criteria
Inclusion criteria: Signing informed consent form Biopsy confirmed lichen planopilaris Age between 18-55 LPPAI>5 Women with reproductive potential who had accepted to use effective contraception during the study period
Exclusion criteria
Exclusion criteria: More than 20% scalp involvement Concurrent alopecia areata Current malignancies History of malignancies in the past 5 years Active infection Pregnancy and lactation Use of systemic drugs such as systemic corticosteroids, cyclosporine, hydroxychloroquine, mycophenolate mofetil in the past 3 months Hypersensitivity to tofacitinib or any components of its formulation Latent TB Hepatitis B and/or C infections Bone marrow suppression (Hb<9g/dl, ANC<1000 cells/mm3, Lymphocyte<500 cells/mm3)
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Lichen Planopilaris Activity Index (LPPAI). Timepoint: Baseline, months 1, 3, 6 and 9. Method of measurement: Lichen Planopilaris Activity Index (LPPAI): Pruritus Pain Burning Erythema Perifullic erythema Perifollicular scale Pull test: anagen/ total Spreading. | — |
Secondary
| Measure | Time frame |
|---|---|
| Patients quality of life. Timepoint: Baseline, months 1, 3, 6 and 9. Method of measurement: Dermatology quality of life questionnaire.;Adverse events. Timepoint: Baseline, months 1, 3, 6 and 9. Method of measurement: Patients self report, physicians observation and lab test abnormalities. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactHamideh Morravej Farshi
Shahid Beheshti University of Medical Sciences
Outcome results
None listed